Potency Validated COVID-19 SARS-CoV-2 neutralizing antibody, Anti-2019-nCoV Spike (Spike RBD domain) monoclonal neutralizing antibody (human IgG1, human IgM, human IgA, mouse IgG1 and Cynomolgus (Non human primate, NHP) IgG1)

Metabolites/Chemicals-IVD

Alzheimer’s Disease (AD) Diagnostics

Bone metabolism & osteoporosis Diagnostics

Monkeypox virus (MPV) antigen & antibody

SARS-CoV-2 Solution

Bovine/Cattle Diagnostics Solution

Diagnostic Cancer

Diagnostic Infectious Disease

Diagnostic Inflammation/ Autoimmune/ Inflammatory Disease

Diagnostic Cardiovascular Disease

Diagnostic Liver Diseases

Diagnostic Lung Injury

Diagnostic Kidney Function (renal damages)

Diagnostic Gastric Disease

Diagnostic Thyroid Diseases

Diagnostic Bowel Disease

Diagnostic Fertility

Diagnostic Diabetes Diseases

Diagnostic Metabolic Disease

Diagnostic Hormone Disorders

Diagnostic Vitamin Deficiency

Diagnostic Fibrinogen Disorders

Diagnostic Neurodegenerative Diseases

Diagnostic Epilepsy

Diagnostic Pain

Diagnostic Multiple Disease

Diagnostic Biology

Diagnostic antibodies and antigens for Companion Animal disease testing

● Dog/Canine

● Cat/Feline

● Rabbit

Diagnostic antibodies and antigens for Swine disease testing

Diagnostic antibodies and antigens for Avian disease testing

Diagnostic antibodies and antigens for Multiple animal disease testing

Diagnostic antibodies and antigens for Ruminant disease testing

● Bovines/Cattle

● Ovines/Sheep

● Caprine/Goat

● Deer

Diagnostic antibodies and antigens for infectious and non-infectious  Equine/Horse disease testing

Diagnostic antibodies and antigens for Fish disease testing

Antibiotics

Food Safety

Agricultural

Allergen

Mycotoxins

Drugs of Abuse

Toxic Heavy Metal

Hormones

Chemicals

Vitamins

Amino Acids

Cell Therapy and Gene Therapy News

Gene Therapy Technical Articles

Technical Resources

How to order

How to pay

Product FAQs

SOCAIL MEDIA

Coronavirus disease 2019 (COVID-19) pandemic is caused by SARS-CoV-2 (SARS2, 2019-nCoV) infection, a newly emerged novel coronavirus spreading worldwide. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2(SARS2, 2019-nCoV) will be greatly important therapeutic agents for the treatment of COVID-19. The availability of therapeutic NAbs against SARS-CoV-2 will offer benefits for the control of the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.

GeneMedi’s NAbs has been validated to reduce SARS-CoV-2 lentivirus-based pseudo virus infectivity and thereby blocking the entry of the Coronavirus to its effector/targeting cell: human ACE2-HEK293T cell.

GeneMedi’s NAbs has been validated by
   1. COVID-19 Spike protein and Spike-RBD protein binding affnity. Click here to Spike-RBD(GMP-V-2019nCoV-SRBD001)
   2. 2019nCoV pseudotyped virus (PSV) based neutralization assay in 293T-ACE2 effector cell. Click here to SARS-CoV-2 Pseudotyped virus
   3. Competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. Click here to ACE2-Fc(GMP-H-ACE2002) 、 SRBD001、 S1S2001

GeneMedi’s Coronavirus neutralizing antibodies (Nabs) can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in SARS-CoV-2 neutralization potency assay.

GeneMedi’s validated COVID-19 neutralizing antibodies group including:
GMP-V-2019nCoV-SnAb001(human IgG1),
GMP-V-2019nCoV-SnAb002(human IgM),
GMP-V-2019nCoV-SnAb003(human IGA),
GMP-V-2019nCoV-SnAb004(mouse IgG1),
GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1)，
GMP-V-2019nCoV-SnAb006(human IgG1),
GMP-V-2019nCoV-SnAb007(human IgG1),
GMP-V-2019nCoV-SnAb008(human IgG1).

Potency Validated COVID-19 SARS-CoV-2 neutralizing antibody

SARS-CoV-2 neutralizing antibody validated post download

–Nab discovery and vaccines evaluation through SARS-CoV-2 wildtype/mutant variants pseudovirus based neutralizing assay(PBNA) and Spike-ACE2 competition binding assay

GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants Pseudovirus (PSV) Based Cell Entry

Figure. The Pseudovirus (PSV) Based Cell Entry assay was performed on 293T-hACE2 cells infected with GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y, D839N, D839E) Pseudovirus (PSV) Infection rate was determined by RFP+GFP+/GFP+ with FACS validation.

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) and Spike RBD protein binding validation

Cat No.ProductEC50 (ng/ml)
GMP-V-2019nCoV-SnAb001Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)5
GMP-V-2019nCoV-SnAb002Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)18
GMP-V-2019nCoV-SnAb003Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)410
GMP-V-2019nCoV-SnAb004Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)6.8
GMP-V-2019nCoV-SnAb005Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)28
Figure. The binding of GeneMedi’s anti-2019-nCoV Spike Neutralizing antibodies (Nabs) to Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) at 5.0ug/ml (100uL/well) was measured by ELISA.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) competitive binding assay validation

Cat No. Product IC50 (ng/ml)
GMP-V-2019nCoV-SnAb001 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) 26.3
GMP-V-2019nCoV-SnAb002 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) 84.2
GMP-V-2019nCoV-SnAb003 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) 20.5
GMP-V-2019nCoV-SnAb004 Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) 81.9
GMP-V-2019nCoV-SnAb005 Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) 243
Figure. GeneMedi’s anti-2019-nCoV Spike Neutralizing antibodies (Nabs) block Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) and hACE2 (GMP-H-ACE2002) binding.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants Pseudovirus (PSV) Based Neutralizing Assay with GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs)

Figure. The Pseudovirus (PSV) Based Neutralizing Assay was performed on 293T-hACE2 cells infected with GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y, D839N, D839E) Pseudovirus (PSV) under treatment of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) . Inhibition rate was determined by comparing the relative RFP+GFP+/GFP+ rate.

Related Products

Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants and Effector cells

Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants and Effector cells

The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. GeneMedi has developed SARS-CoV-2 wildtype and mutation variants pseudovirus production system, from which the SARS-CoV-2 wildtype and mutation variants pseudotyped virus can be handled in biosafety level 2 (BSL-2).

GeneMedi develop COVID-19 related SARS-CoV-2 (2019-nCoV) Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants including D614G, N501Y, E484K, E484Q, L452R, K417N, K417T, S477N, S477G, D253G, and so on.

GeneMedi’s Pseudovirus Based Neutralization Assay (PBNA) is a conventional assay method that is suitable for High-Throughout Screening (HTS) without live virus engaged. The Pseudovirus Based Neutralization Assay can be used for evaluating:

1) Neutralizing antibodies
2) Peptides blockers (peptide inhibitors)
3) Types of Vaccines3
4) Compounds targeting Spike induced cell-fusion.

GeneMedi offers:

1.SARS-CoV-2 Pseudotyped virus packaging and production
2.Effector cells: human ACE2 overexpression stable HEK293T cell lines
3.SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay service.

For inquiry please click here to contact us or send email to [email protected]

2019 nCoV (SARS2 coronavirus) Antibodies for COVID-19

Protocol of SARS-CoV-2 Pseudovirus (PSV)-Based Neutralization Assay For Vaccines, therapeutic antibodies, peptides and compounds against COVID-19

Protocol Download

SARS-CoV-2 (2019nCoV) pseudotype virus (pseudovirus, PSV) for COVID-19 related vaccines and neutralizing antibodies evaluation.

The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. Due to its high pathogenicity and infectivity1, live SARS-CoV-2 should be handled under biosafety level 3 (BSL-3) conditions. GeneMedi has developed SARS-CoV-2 pseudovirus production system, from which the SARS-CoV-2 pseudotyped virus can be handled in biosafety level 2 (BSL-2)2.

GeneMedi’s SARS-CoV-2 (2019nCoV) pseudotype virus (pseudovirus, PSV) based neutralization assay is a standard evaluation procedure for COVID-19 related vaccines and neutralizing antibodies potency evaluation. GeneMedi’s SARS-CoV-2 PSV is the core ingredient of diagnostics for neutralization serology after vaccinotherapy.

GeneMedi’s SARS-CoV-2 pseudotyped virus includes wildtype and the spike mutation variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E: D839Y, D839N, D839E). The GeneMedi’s SARS-CoV2 PSV panel help for all-in-one vaccinotherapy evaluation.

Application-SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay3

In the Pseudovirus-Based Neutralization Assay (PBNA), the inhibition of viral entry into cells by neutralizing antibodies is correlated to the decreased levels of firefly luciferase signals in the ACE2 expression cells (hACE2-HEK293T, Cat. GM-SC-293T-hACE201) . GeneMedi’s Pseudovirus Based Neutralization Assay (PBNA) is a conventional assay method that is suitable for High-Throughout Screening (HTS) without live virus engaged. The Pseudovirus Based Neutralization Assay can be used for evaluating: 1) Neutralizing antibodies (NAbs)3,4 2) Peptides blockers5,6 (peptide inhibitors) or protein7,8 3) Types of Vaccines (Immunized serum)9 4) Compounds targeting Spike induced cell-fusion10.

Protocol of SARS-CoV-2 Pseudovirus (PSV)-Based Neutralization Assay

Materials 1. SARS-CoV-2 Pseudovirus-RFP-fLuciferase (GM-2019nCoV-PSV01) 2. Efforter cell: Alternative A. hACE2-HEK293T stable cell line (GM-SC-293T-hACE2-01) B. Wildtype HEK293T cell line, hACE2 vector for transfection (GMV-V-2019nCoV-041) Protocol If your efforter cell is hACE2-HEK293T stable cell line, please begin in Step 2. 1.Transfect HEK293T with hACE2-GFP vector (GMV-V-2019nCoV-041) 24hrs before planting the cell into 96-well. 2.Plant the hACE2-HEK293T into 96-well (5,000~10,000 per well) overnight before SARS-CoV-2 PSV infection. 3.Generation of 100ul PSV-Sample mixture:
100ul PSV-Sample mixture Volume
GM-2019nCoV-PSV01* 50ul or 5ul
Sample(NAbs, peptides, serum, etc) flexible (According to your own products)
Total add culture medium to 100ul
* For GM-2019nCoV-PSV01-1, add 50ul in recommendation (range from20ul~100ul). For GM-2019nCoV-PSV01-2, add 5ul in recommendation. (range from2ul~10ul).

Incubate PSV-Sample mixture for 1h at room temperature.

4.Remove the medium of efforter cell in 96-well, add 100ul PSV-Sample mixture to 96well cells for infection. 3wells for a group.

5.Fluorescence imaging (RFP) 72hrs after SARS-CoV-2 PSV infection. The firefly luciferase reporter is measured by following the Promega Luciferase Assay Reagent manual.

Tips

 

If your samples are serum
A standard curve should be generated using serially diluted Nabs (neutralizing antibodies) as a positive control.

If your samples are therapeutic antibodies or peptides candidates
Dilute the samples into concentration gradient for IC50 value evaluation.

GeneMedi SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry

Data Post Download
Figure. GeneMedi-SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry validation with fluorescence(A), Luciferase activity (B) and FACS (C) after 72 hours of HEK293T infection. hACE2 significantly enhanced the infection efficiency of the SARS-CoV-2 PSV. GeneMedi SARS-CoV-2 PSV-Luciferase (Cat.GM-2019nCoV-PSV01) is recombinant pseudotyped lentiviral particles containing SARS-CoV-2 spike protein to mimic SARS-CoV-2 (2019nCoV) cell infection. GM-2019nCoV-PSV01 is a powerful tool for SARS-CoV-2 related vaccine efficacy evaluation, neutralizing antibodies, peptides blockers competitors neutralization assay, and tissue-specific infection determination.

References

1 XiaolongCai. An Insight of comparison between COVID-19 (2019-nCoV) and SARS-CoV in pathology and pathogenesis. Preprint, doi:10.31219/osf.io/hw34x (2020, paper of GeneMedi). 2 Jean K. Millet1, Tiffany Tang3, Lakshmi Nathan3, Javier A. Jaimes4, Hung-Lun Hsu3,5, & Susan Daniel3, G. R. W. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp, doi:10.3791/59010 (2019). 3 Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9, 680-686, doi:10.1080/22221751.2020.1743767 (2020). 4 Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol, doi:10.1016/j.it.2020.03.007 (2020). 5 Zhang, G., Pomplun, S., Loftis, A. R., Loas, A. & Pentelute, B. L. The first-in-class peptide binder to the SARS-CoV-2 spike protein. doi:10.1101/2020.03.19.999318 (2020). 6 Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30, 343-355, doi:10.1038/s41422-020-0305-x (2020). 7 Monteil, V. et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, doi:10.1016/j.cell.2020.04.004 (2020). 8 Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun 11, 2070, doi:10.1038/s41467-020-16048-4 (2020). 9 HuajunBai, X., XiaolongCai. Vaccines And Advanced Vaccines: -A landscape for advanced vaccine technology against infectious disease ,COVID-19 and tumor. Preprint, doi:10.31219/osf.io/ypgx4 (2020). 10 Hoffmann, M. et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, doi:10.1101/2020.01.31.929042 (2020).